Time Prediction and Cerebellum: Magnetic Transcranial Stimulation (TMS) in Healthy Volunteers

Inclusion criteria

• Participant, male or female, between 18 and 60 years old
• Subject affiliated to a social health insurance scheme (beneficiary or entitled person)
• Subject who has dated and signed an informed consent form
• For a woman of childbearing age, negative pregnancy test and effective contraception throughout the study

Exclusion criteria

• - Participant with substance use disorders (as defined by DSM-V)
• Participants taking benzodiazepines and related substances (in the period before inclusion, for a duration equivalent to 5 half-lives of the product), cannabis (in the 2 months before inclusion) or hallucinogenic substances (in the period before inclusion, for a duration equivalent to 5 half-lives of the product).
• Participant with neurological pathology or sequelae
• Participant with Attention Deficit Hyperactivity Disorder (ADHD)
• Participant with a borderline personality disorder
• Participant with disabling sensory impairments, including visual acuity (corrected, if applicable) < 0.8 (due to use of visual material) (Freiburg Vision Test, Bach 1996)
• Participant deprived of liberty or subject to the safeguard of justice
• Participant under guardianship or curatorship
• Participant in a period of exclusion defined by another clinical study or participant in a study that may impact on research results
• Pregnant or breastfeeding woman
• Subject with a contraindication to performing an MRI or TMS: presence of non-removable ferromagnetic body, prosthesis, pacemaker, medication delivered by an implanted pump, vascular clip or stent, heart valve or ventricular lead, certain intracerebral clips, cochlear implants, history of epilepsy, skin pathology at the point of contact with the electrodes.
• Subject with a history of major neurological or psychiatric illness with current psychotropic medication (i.e., antidepressant, thyroid regulator, antipsychotic, benzodiazepine and related drugs, or hypnotic).